The purpose of this study was to assess the acute psychoactive and physiological properties of 5-HT 3 antagonism using ondansetron as a probe. Ondansetron is used clinically as an anti-emetic but is also under treatment consideration for a range of psychiatric disorders including drug abuse. A 15 min infusion of 40 mg ondansetron, a 1 min infusion of 25 mg of cocaine (positive control) and their respective placebos were tested intravenously in eight volunteers with histories of drug abuse in a blinded cross-over study. Ondansetron responses could not be distinguished from the placebo. Cocaine produced typical subjective and physiological effects. These findings indicate that the prototypic 5-HT 3 receptor antagonist ondansetron does not produce acute psychoactive effects when infused at doses of up to 40 mg and has no rewarding effects with this regime.
Aapro M.S. (1991) 5-HT3 receptor antagonists. An overview of their present status and future potential in cancer therapy-induced emesis . Drugs42: 552-568
2.
Barnes J.M., Costall B., Coughlan J., Domeney J.M., Gerrard PA, Kelley M.E., Naylor R.J., Onaivi R.S., Tomkins D.M., Tyers M.B. (1990) The effects of ondansetron, a 5-HT3 receptor antagonist, on cognition in rodents and primates. Pharmacol Biochem Behav35: 955-962
Brittain R., Butler A., Coates I.H., Fortune D.H., Hagan R., Hill J.M., Humber D.C., Humphrey P PA, Ireland S.J., Jack D., Jordan C.C., Oxford A., Straughan D.W., Tyers M.D. (1987) GR38032F, a novel selective 5HT3 receptor antagonist. Br J Pharmacol90:87
5.
Bunce K., Tyers M., Beranek P. (1991) Clinical evaluation of 5-HT3 receptor antagonists as anti-emetics. Trends Pharmacol Sci12: 46-48
6.
Carboni E., Acquas C., Leone P., Perrezani L., Di Chiara G. (1988) 5-HT3 receptor antagonists block morphine- and nicotine-induced place preference conditioning. Eur J Pharmacol151:159-160
7.
Cochran W.G., Cox G.M. (1957) Experimental designs, 2nd edn. John Wiley and Sons, Inc., NewYork
8.
Costall B., Domeney A.M., Naylor R.J., Tyers M.B. (1987) Effects of the 5-HT3 antagonist, GR 38932F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain. Br J Pharmacol92: 881-894
9.
Costall B., Naylor R.J., Tyers M.B. (1990) The psychopharmacology of 5-HT3 receptors . Pharmacol Ther47: 181-202
10.
Fischman M., Schuster C.W. (1980) Cocaine effects in sleep-derived humans. Psychopharmacology72:1-8
11.
Fozard J.R., Maborok-ali Atm, Newgrosh G. (1977) Selective blockade of presynaptic tryptamine receptors by (-)-cocaine and (+)-cocaine. Br J Pharmacol61:130-131
12.
Griffith JD, Nutt JG, Jasinski DR (1975) A comparison of fenfluramine and amphetamine in man. Clin Pharmacol Ther18: 563-570
13.
Griffith JD, Jasinski DR, Casten G.P., McKinney GR (1986) Investigation of the abuse liability of buspirone in alcohol-dependent patients. Am J Med80 (Suppl 3B): 30-35
14.
Jasinski DR (1977) Assessment of the abuse potentiality of morphine-like drugs (methods used in man). In Martin W R (ed.), Handbook of experimental pharmacology vol. 45/1. Drug addiction 1: morphine, sedative hypnotic and alcohol dependence. Springer-Verlag, Heidelberg, pp. 197-258
15.
Jasinski DR, Henningfield J.E. (1989) Human abuse liability assessment by measurement of subjective and physiologic effects. In Fischman M W, Mello N K (eds), Testing for abuse liability of drugs in humans. NIDA research monograph no. 92, pp.73-100
16.
Johnson BA, Campling GM, Griffiths P., Cowen PJ (1993) Attenuation of some alcohol-induced mood changes and the desire to drink by some alcohol-induced mood changes and the desire to drink by 5HT3 receptor blockade: a preliminary study in healthy volunteers. Psychopharmacology112:142-144
17.
Preston K.L., Jasinski DR, Testa M. (1991) Abuse potential and pharmacological comparison of tramadol and morphine. Drug Alcohol Depend27: 7-17
18.
Preston K.L., Sullivan J.T., Strain E.C., Bigelow G.E. (1992) Effects of cocaine alone and in combination with bromocriptine in human cocaine abusers. J Pharmacol Exp Ther262: 279-291
19.
Reith M E A (1990) 5 -HT3 receptor antagonists attenuate cocaine-induced locomotion in mice. Eur J Pharmacol186: 327-330
20.
Sullivan J.T., Jasinski D.R., Preston K.L., Testa M.P., Bell J.M. (1992a) Cocaine blocking effects of ondansetron. In Harris L (ed.), Problems of drug dependence 1991: Proceedings of the 53rd Annual Scientific Meeting. The Committee on Problems of Drug Dependence, Inc., US Department of Health and Human Services. NIDA research monograph no. 119, p. 466
21.
Sullivan J.T., Preston K.L., Testa M.P., Busch M., Jasinski D.R. (1992) Evaluation of the psychoactivity and abuse liability of the 5-HT1D agonist sumatriptan. Clin Pharmacol Ther52: 635-642
22.
Sullivan J.T., Testa M.P., Preston K.L., Blum P., Jasinski D.R. (1994) Psychoactivity of ritanserin and its interaction with intravenous cocaine. In Harris L (ed.), Problems of drug dependence 1993: Proceedings of the 55th Annual Scientific Meeting. The College on Problems of Drug Dependence, Inc., US Department of Health and Human Services. NIDA research monograph no. 141, p. 377
23.
Tricklebank M.D. (1989) Interactions between dopamine and 5-HT3 receptors suggest new treatments for psychosis and drug addiction. Trends Pharmacol Sci10:127-129
24.
Vocci FJ (1989) The necessity and utility of abuse liability evaluations in human subjects: the FDA perspective. In Fischman M W, Mello N K (eds), Testing for abuse liability of drugs in humans. NIDA research monograph no. 92, pp.7-20
25.
Weiner N. (1985) Atropine, scopolamine and related drugs. In Gilman A G, Goodman L S, Rall T W, Murod F (eds), The pharmacological basis of therapeutics, 7th edn. Macmillan Publishing Company, NewYork
